Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4651 Neuroendocrine hyperplasia of infancy (NEHI) vs. diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): What is the difference?

Introduction: Neuroendocrine Hyperplasia of Infancy (NEHI) is a rare disease that belongs to the group of interstitial lung disease in children; characterised by hypoxemia, tachypnoea, and respiratory distress, often misdiagnosed as reactive airway disease or bronchiolitis. The diagnosis relies on histologic evaluation. We describe the clinical presentation and paraclinical characteristics of paediatric patients with NEHI.

Conference:

Presenting Author:

Authors: González Devia D, Restrepo Gualteros S, Ortiz Pérez M, Fernández Hernández B,

Keywords: Neuroendocrine Hyperplasia of Infancy, Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, child,

#4572 Steroid dosing to prevent tumour flare reaction with 177Lu-DOTATATE

Introduction: Tumour flare reactions including increased pain and small bowel obstruction (SBO) have been reported in patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) receiving 177Lu-DOTATATE. Retrospective reviews report tumour flare reactions in 6 to 40 percent of high-risk patients receiving 177Lu-DOTATATE and report success with using corticosteroid prophylaxis to prevent tumour flare recurrence with subsequent doses of 177Lu-DOTATATE (Strosberg, et al., 2021; Salner, et al., 2020).

Conference:

Presenting Author:

Authors: Cass A, Skotte E, Wheless M, Stockton S, Ramirez R,

Keywords: 177Lu-DOTATATE, corticosteroid prophylaxis, tumour flare,

#4022 Immediate and sustained response of hypoglycaemia to Streptozotocin-based chemotherapy in metastatic Insulinoma: A case report

Introduction: Hypoglycaemia due to insulin production from insulinomas can be challenging to manage. The evidence base for systemic treatment selection is small.

Conference:

Presenting Author:

Authors: Sherriff D, Flanagan D,

Keywords: insulinoma, hypoglycaemia, streptozotocin,

#2753 Risk of PRRT-Associated Bowel Obstruction in Patients with Mesenteric/Peritoneal Disease and Potential Role of Corticosteroids in Treatment

Introduction: Although radiation-induced mesenteritis or peritonitis can potentially exacerbate risk of bowel obstruction, there are no data in the literature on incidence of intestinal obstruction related to peptide receptor radiotherapy (PRRT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Al-Toubah T, El-Haddad G, Pelle E, Strosberg J,

Keywords: PRRT, Lutetium-dotatate, Bowel obstruction, Peritoneal carcinomatosis, Steroids,

#423 Case Report : A Rare Cause of Retroperitoneal Fibrosis Responding to Steroids

Introduction: Retroperitoneal fibrosis is a rare inflammatory disease. Neuroendocrine tumors are a heterogenous group that arise from enterochromaffin cells, most commonly in the gastrointestinal tract. Their capacity to secrete hormones, five HT, tachykinins etc, are responsible for symptoms known as carcinoid syndrome. However NETS, particularly arising from the midgut, can cause fibrosis. This can result in bowel obstruction, but also cause fibrosis in the retroperitoneum, lungs and cardiac valvular fibrosis.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Mandair D, Mangat K, Malaki M, Shah T,

Keywords: neuroendocrine tumor, fibrosis, steroids,